Graduate School of Medical Sciences
A partnership with the Sloan Kettering Institute

News

A protein called CDC7, long thought to play an essential role early in the cell division process, is in fact replaceable by another protein called CDK1, according to a study by investigators at Weill Cornell Medicine and the Dana-Farber Cancer Institute. The finding represents a fundamental advance in cell biology and may lead to new cancer therapies, since cancers frequently alter the molecular machinery of cell division to sustain their rapid growth.

The study, published online May 4...

Read More

Using cutting-edge techniques, Weill Cornell Medicine and Memorial Sloan Kettering investigators have visualized the structure of a receptor targeted by an anti-cancer immunotherapy. The new information may help scientists improve this type of cancer treatment.

The study, published Feb. 25 in Science Advances, used cryo-electron microscopy (cryo-EM) to reveal the full-length structure of the glucocorticoid-induced tumor necrosis factor receptor (GITR), an advance over previous studies...

Read More

Two multi-institutional teams led by Weill Cornell Medicine scientists have been awarded grant support from the Starr Cancer Consortium. Both grants will fund work applying new technologies to develop more detailed knowledge of tumor biology, with one team focusing on Hodgkin lymphoma and the other on the purity of tumor samples on pathology slides.

The Starr Cancer Consortium, established in 2006, is a collaboration among five leading research institutions: The Broad Institute of MIT...

Read More

Investigators from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have discovered how a drug for multiple sclerosis interacts with its targets, a finding that may pave the way for better treatments.

The study, published Feb. 8 in Nature Communications, details the precise molecular structure of the multiple sclerosis drug siponimod as it interacts with its target, the human S1P receptor 1 (S1P1), and off-target receptors using a cutting-edge electron microscopy...

Read More

Two Weill Cornell Medicine physician-scientists, Dr. Randy Longman and Dr. Robert Schwartz, have been elected as members of the American Society for Clinical Investigation.

The American Society for Clinical Investigation (ASCI) is one of the nation’s oldest nonprofit medical honor societies and focuses on the unique role of physician-scientists in research, clinical care and medical education. It is comprised of more than 3,000 physician-scientists serving in the upper ranks of...

Read More

Scientists at the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine have developed a pipeline that enables genetic manipulation of nonmodel gut bacteria. The pipeline will allow scientists to study the biological roles of these bacteria, which are increasingly recognized as key factors in health and disease, at the single-gene level.

Scientists have developed advanced genetic tools for some model gut bacteria, such as E. coli, but have lacked...

Read More

A protein that masterminds the way DNA is wrapped within chromosomes has a major role in the healthy functioning of blood stem cells, which produce all blood cells in the body, according to a new study from researchers at Weill Cornell Medicine.

The protein, known as histone H3.3, organizes the spool-like structures around which DNA is wrapped in plants, animals and most other organisms. Histones enable DNA to be tightly compacted, and serve as platforms for small chemical...

Read More

Multiple changes in brain cells during the first month of embryonic development may contribute to schizophrenia later in life, according to a new study by Weill Cornell Medicine investigators.

The researchers, whose study was published in Molecular Psychiatry on Nov. 17, used stem cells collected from patients with schizophrenia and people without the disease to grow 3-dimensional “mini-brains” or organoids in the laboratory. By comparing the development of both sets of organoids, they...

Read More

Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.

Their research, published Dec. 7 in Cell Reports, suggests that cancer treatment could potentially be tailored by age. The study also identified pre-existing drugs that could target mutations predominantly found in younger cancer patients—promising candidates for future clinical research.

“...

Read More

A group of immune cells that normally protect against inflammation in the gastrointestinal tract may have the opposite effect in multiple sclerosis (MS) and other brain inflammation-related conditions, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian researchers. The results suggest that countering the activity of these cells could be a new therapeutic approach for such conditions.

The researchers, who reported their finding Dec. 1 in Nature, were studying a...

Read More

Weill Cornell Medicine Graduate School of Medical Sciences 1300 York Ave. Box 65 New York, NY 10065 Phone: (212) 746-6565 Fax: (212) 746-8906